# Maha Radhakrishnan

> Maha Radhakrishnan is a Series B investor at Sofinnova Investments backing Therapeutics. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Sofinnova Investments](https://shizune.co/investors/profile/sofinnova-ventures)
- Location: Menlo Park, United States
- Total investments: 2
- Last investment: Jul 2026
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/maha-radhakrishnan-80297728
- Website: https://x.com/MahaRadhakrish2

Maha Radhakrishnan is a Series B investor at Sofinnova Investments in Menlo Park focused on Therapeutics and Biopharma. Maha Radhakrishnan is based out of Menlo Park, California, and is the Executive Partner at Sofinnova Investments. Maha Radhakrishnan is the Board of Director of Entrada Therapeutics. Maha previously worked as Group Senior Vice President and Chief Medical Officer at Biogen. Maha Radhakrishnan attended Peoples' Friendship University of Russia.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 2 | 100% |
| Biopharma | 1 | 50% |
| Health Care | 1 | 50% |
| Life Science | 1 | 50% |
| Biotechnology | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Claris Biotherapeutics | Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment. | $118M | Series B | Jul 28, 2026 |  |
| City Therapeutics | City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M | Series B | Jun 08, 2026 |  |

2 of 2 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together
- [ADAR1 Capital Management](https://shizune.co/investors/profile/adar1-capital-management) — VC Fund, 1 deal together
- [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 1 deal together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 1 deal together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 1 deal together

## About Sofinnova Investments

VC Fund · Menlo Park, United States

Sofinnova Ventures has partnered with entrepreneurs to secure initial funding, build successful teams, win key customers, and navigate acquisitions and IPOs. Sofinnova Ventures invests in Life Science and Technology start-ups. Their professionals are seasoned business operators, possessing deep domain and investment expertise. They know how to helpentrepreneurs build successful, global businesses.

5 contacts available at Sofinnova Investments.

| Name | Title | Profile |
| --- | --- | --- |
| Jakob Dupont | Executive Partner | https://shizune.co/investors/profile/jakob-dupont-e61e |
| James Healy | General Partner & President | https://shizune.co/investors/profile/james-i-healy |
| Jonathan Leff | Executive Partner, Private Equity | https://shizune.co/investors/profile/jonathan-leff-6bb8 |
| Lesley Weber | San Diego Office Manager & EA | https://shizune.co/investors/profile/lesley-weber |
| Maha Radhakrishnan | Executive Partner | https://shizune.co/investors/profile/maha-radhakrishnan |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Maha Radhakrishnan invest in?

Maha Radhakrishnan invests primarily in Therapeutics, Biopharma and Health Care startups, most often at Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Maha Radhakrishnan last invest?

The most recent investment recorded for Maha Radhakrishnan closed in Jul 2026. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co